Familial Hyperaldosteronism Type III: A Patient Guide

Receiving a diagnosis of a rare genetic condition can feel overwhelming, but understanding the underlying biology is the first step toward taking control of your care. Familial Hyperaldosteronism Type III (FH-III) is a rare genetic condition that fundamentally changes how the body manages salt, water, and blood pressure. It is caused by a mutation in the KCNJ5 gene, which creates a “leaky” potassium channel in the adrenal glands ^[1]. This genetic error acts like a stuck accelerator, forcing the adrenal glands to continuously produce massive amounts of the hormone aldosterone. This hormone surge tells the kidneys to retain sodium and flush out potassium, leading to severe high blood pressure that often begins in childhood or early adulthood ^[2][3].

Living with FH-III requires navigating a unique medical path that differs significantly from more common forms of high blood pressure. Because the root cause is genetic and present in every cell of the adrenal glands, the condition is often “resistant,” meaning standard blood pressure medications may struggle to keep up with the hormone levels. Early identification through genetic testing is a critical milestone; it not only confirms the diagnosis but can also help patients avoid some of the invasive diagnostic tests usually required for other types of adrenal disease ^[4][5]. A confirmed pathogenic KCNJ5 variant may make procedures like adrenal venous sampling unnecessary when bilateral disease is clinically clear, but it does not replace the rest of the medical evaluation, and testing remains individualized.

The journey through FH-III often involves a central choice between long-term medical management and surgical intervention. While medications called mineralocorticoid receptor antagonists can block the effects of aldosterone, the extreme hormone production in some severe cases of FH-III may lead specialists to consider the removal of both adrenal glands (bilateral adrenalectomy) to protect the heart and kidneys ^[6][5]. There is no universal deadline or requirement for surgery, and some patients remain medically managed. If surgery is chosen, it effectively exchanges the dangers of high aldosterone for a new state called adrenal insufficiency. This requires a lifelong commitment to replacing essential hormones with daily medication and learning to manage the body’s response to stress and illness ^[7][8].

Ultimately, managing FH-III is about more than just numbers on a blood pressure monitor; it is about building a specialized care team to protect long-term health and empower the family. Because the condition is inherited in an autosomal dominant pattern, a diagnosis often provides a “map” for the health of other family members as well ^[9]. While the path is complex, modern genetic insights and specialized care strategies allow patients and parents to stay ahead of the condition, making informed decisions that prioritize a full and active life ^[4][6].

What is Known and What Remains Uncertain

Because FH-III is exceptionally rare, much of what we know comes from small families and case reports. There is no universally predictable progression or genotype-based surgery rule, and severity can vary significantly between individuals. Routine monitoring and shared decision-making with your specialist are your most important tools.